CDKN2A and neoplasm: The case published by Verbeek et al. [24] in 2023 introduced a tumour that displayed a positive amplification of the MDM2 gene plus a homozygous loss of the CDKN2A (cyclin-dependent kinase inhibitor 2A) gene on 9p21 in a 4-year-old child.